These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 9285541)
41. [High dosage therapy and autologous peripheral stem cell transplantation in breast carcinoma]. Kier P; Ruckser R; Buxhofer V; Habertheuer KH; Zelenka P; Tatzreiter G; Hübl G; Kittl E; Hauser A; Sebesta C; Hinterberger W Acta Med Austriaca Suppl; 2000; 52():33-6. PubMed ID: 11261276 [TBL] [Abstract][Full Text] [Related]
42. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit. Kurian S; Qazilbash M; Fay J; Wolff S; Herzig R; Hobbs G; Bunner P; Weisenborn R; Aya-Ay M; Lynch J; Ericson S Breast J; 2006; 12(6):531-5. PubMed ID: 17238982 [TBL] [Abstract][Full Text] [Related]
43. High-dose chemotherapy and autologous stem cell support followed by post-transplant doxorubicin and taxol as initial therapy for metastatic breast cancer: hematopoietic tolerance and efficacy. deMagalhaes-Silverman M; Hammert L; Lembersky B; Lister J; Rybka W; Ball E Bone Marrow Transplant; 1998 Jun; 21(12):1207-11. PubMed ID: 9674853 [TBL] [Abstract][Full Text] [Related]
44. Feasibility of high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children with high grade osteosarcoma. Miniero R; Brach del Prever A; Vassallo E; Nesi F; Busca A; Fagioli F; Albiani R; Picci P; Bacci G; Madon E Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S37-40. PubMed ID: 9989888 [TBL] [Abstract][Full Text] [Related]
45. TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer. Razis ED; Samonis G; Cook P; Beer M; Mittelman A; Lake DE; Feldman EJ; Puccio C; Ahmed T J Med; 1994; 25(3-4):241-50. PubMed ID: 7996067 [TBL] [Abstract][Full Text] [Related]
46. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery. Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989 [TBL] [Abstract][Full Text] [Related]
47. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. Brugger W; Fetscher S; Hasse J; Frommhold H; Pressler K; Mertelsmann R; Engelhardt R; Kanz L Semin Oncol; 1998 Feb; 25(1 Suppl 2):42-8. PubMed ID: 9535211 [TBL] [Abstract][Full Text] [Related]
48. High-dose chemotherapy, autologous bone marrow or stem cell transplantation and post-transplant consolidation chemotherapy in patients with advanced breast cancer. Tallman MS; Rademaker AW; Jahnke L; Brown SG; Bauman A; Mangan C; Kelly C; Rubin H; Kies MS; Shaw J; Kiel K; Gordon LI; Gradishar WJ; Winter JN Bone Marrow Transplant; 1997 Nov; 20(9):721-9. PubMed ID: 9384473 [TBL] [Abstract][Full Text] [Related]
49. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. Nieto Y; Cagnoni PJ; Shpall EJ; Xu X; Murphy J; Vredenburgh J; Chao NJ; Bearman SI; Jones RB Clin Cancer Res; 1999 Nov; 5(11):3425-31. PubMed ID: 10589754 [TBL] [Abstract][Full Text] [Related]
50. Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. Fields KK; Elfenbein GJ; Perkins JB; Hiemenz JW; Janssen WE; Zorsky PE; Ballester OF; Kronish LE; Foody MC Semin Oncol; 1993 Oct; 20(5 Suppl 6):59-66. PubMed ID: 8211217 [TBL] [Abstract][Full Text] [Related]
51. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J; J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969 [TBL] [Abstract][Full Text] [Related]
52. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer. deMagalhaes-Silverman M; Bloom E; Lembersky B; Lister J; Pincus S; Rybka W; Voloshin M; Wilson J; Ball E Clin Cancer Res; 1997 Feb; 3(2):193-7. PubMed ID: 9815672 [TBL] [Abstract][Full Text] [Related]
53. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer. Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897 [TBL] [Abstract][Full Text] [Related]
54. High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome. Ahmed T; Kancherla R; Qureshi Z; Mittelman A; Seiter K; Mannancheril A; Puccio C; Chun HG; Bar M; Lipshutz M; Ali MF; Goldberg R; Preti R; Lake D; Durrani H; Farley T Bone Marrow Transplant; 2000 May; 25(10):1041-5. PubMed ID: 10828863 [TBL] [Abstract][Full Text] [Related]
55. A phase II study of repetitive cycles of dose-intense carboplatin plus paclitaxel chemotherapy and peripheral blood stem cells in metastatic breast cancer. Ford C; Spitzer G; Reilly W; Adkins D Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-81-S17-86. PubMed ID: 9374101 [TBL] [Abstract][Full Text] [Related]
57. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS). Bernbeck B; Bahci S; Meisel R; Troeger A; Schönberger S; Laws HJ; Kramm C; Wessalowski R; Koscielniak E; Dilloo D; Göbel U Klin Padiatr; 2007; 219(6):318-22. PubMed ID: 18050041 [TBL] [Abstract][Full Text] [Related]
58. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Gisselbrecht C; Extra JM; Lotz JP; Devaux Y; Janvier M; Peny AM; Guillevin L; Bremond D; Delain M; Herbrecht R; Lepage E; Maraninchi D Bone Marrow Transplant; 1996 Nov; 18(5):857-63. PubMed ID: 8932837 [TBL] [Abstract][Full Text] [Related]
59. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience. Laport GF; Grad G; Grinblatt DL; Bitran JD; Williams SF Bone Marrow Transplant; 1998 Jan; 21(2):127-32. PubMed ID: 9489628 [TBL] [Abstract][Full Text] [Related]
60. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Vahdat LT; Balmaceda C; Papadopoulos K; Frederick D; Donovan D; Sharpe E; Kaufman E; Savage D; Tiersten A; Nichols G; Haythe J; Troxel A; Antman K; Hesdorffer CS Bone Marrow Transplant; 2002 Aug; 30(3):149-55. PubMed ID: 12189532 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]